Prestige BioPharma receives EUGMP certification for Tuznue® (biosimilar trastuzumab) manufacturing facility

Feb 21, 2022

Prestige BioPharma announced that the manufacturing facility for Tuznue® (biosimilar trastuzumab) has received EUGMP certification.  Tuznue® is under Marketing Authorisation Application review in the EU, Canada and South Korea.

Print Page Mail Article